ReviewFrontiers in public health2022
The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic.
Review in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
140 citing papers in PubMed, 281 citations in OpenAlex.
- L-fucose-dependent biofilm formation byBiofilm · 2026Article
- In vitro activity and comparative efficacy of novel nitrofuran-containing ciprofloxacin analogs against bacterial pathogens including ciprofloxacin-resistant Staphylococcus aureus.The Journal of antibiotics · 2026Article
- Environmental persistence of fluoroquinolones: Reverse-phase high-performance liquid chromatography-based surveillance of contamination in water, soil, and food sources.Journal of the science of food and agriculture · 2026Article
- Article
- Phenotypic and phylogenomic characterization of Lactococcus garvieae isolates from rainbow trout (Oncorhynchus mykiss) in Türkiye.Veterinary research communications · 2026Article
- Assessment of Enterococcus faecalis biofilm response to amoxicillin and ciprofloxacin using a dynamic in vitro pharmacokinetic-pharmacodynamic model of catheter-associated urinary tract infection.The Journal of antimicrobial chemotherapy · 2026Article
- Green stability-indicating RP-HPLC method for simultaneous bioanalysis of tedizolid phosphate and ciprofloxacin in human plasma.Scientific reports · 2026Article
- Eco-Friendly Access to Indenodiazepinones fromACS medicinal chemistry letters · 2026Article
- Prevalence and Antimicrobial Resistance Profiles of Salmonella Isolated From Table Eggs in Rupandehi, Nepal.Veterinary medicine and science · 2026Article
- Manganese-Doped Carbon Dots for Sensitive Fluorescence Detection of Ciprofloxacin in Environmental and Pharmaceutical Samples.Biosensors · 2026Article
- Antibiotic exposure and recovery of persister states influence virulence phenotypes in Pseudomonas aeruginosa.Archives of microbiology · 2026Article
- Assessing ZnScientific reports · 2026Article
- Biotherapeutic strategies for quorum quenching in Salmonella Typhi: a review.Archives of microbiology · 2026Review
- L-Fucose-Dependent Biofilm Formation bybioRxiv : the preprint server for biology · 2026Article
- Advances in Ciprofloxacin Derivatives: Emerging Strategies to Combat Antimicrobial Resistance.Topics in current chemistry (Cham) · 2026Review
- Biofilm Formation and Antibiotic Susceptibility Patterns in Contact Lens-Associated Bacteria.Korean journal of ophthalmology : KJO · 2026Article
- Genomic analysis of Vibrio cholerae in Western Kenya (2015-2023) reveals persistence of pandemic ST69 and presence of the European-associated ST8 lineage.BMC genomics · 2026Article
- Study of the Impact of Antibiotic Combinations Used in Urinary Tract Infections on the Effectiveness of Antimicrobial Therapy.Journal of clinical medicine · 2026Article
- Whole-genome characterization of clinical Enterococcus faecalis and Staphylococcus epidermidis Isolates reveals mecA-positive E. faecalis and a shared lnu(A)-rep7a resistance plasmid in Türkiye.BMC microbiology · 2026Article
- Cross-sectoral antimicrobial resistance patterns ofVeterinary world · 2026Article
80 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For around three decades, the fluoroquinolone (FQ) antibiotic ciprofloxacin has been used to treat a range of diseases, including chronic otorrhea, endocarditis, lower respiratory tract, gastrointestinal, skin and soft tissue, and urinary tract infections. Ciprofloxacin's main mode of action is to stop DNA replication by blocking the A subunit of DNA gyrase and having an extra impact on the substances in cell walls. Available in intravenous and oral formulations, ciprofloxacin reaches therapeutic concentrations in the majority of tissues and bodily fluids with a low possibility for side effects. Despite the outstanding qualities of this antibiotic,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.